Every clinical trial is impacted by many variables—expected and unexpected--but the COVID-19 pandemic has created an array of unique challenges to developing treatments, not the least of which being the ongoing evolution of the virus itself into subvariants with differing characteristics.
In this paper, we examine the implications of the virus’ continual evolution on case reporting and disease management, identify tools that can assist in predicting disease patterns, share insights on how disease research will evolve and provide recommendations for standing up future COVID-19 trials.
Download the white paper.
